Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial

Lars Søndergaard; Daniel Andreas Steinbrüchel; Nikolaj Ihlemann; Henrik Nissen; Bo Juel Kjeldsen; Petur Petursson; Thuc Anh Ngo; Niels Thue Olsen; Yanping Chang; Olaf Walter Franzen; Thomas Engstrøm; Peter Clemmensen; Peter Skov Olsen; Hans Gustav Hørsted Thyregod

doi:10.1161/CIRCINTERVENTIONS.115.003665

Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial

Lars Søndergaard, Daniel Andreas Steinbrüchel, Nikolaj Ihlemann, Henrik Nissen, Bo Juel Kjeldsen, Petur Petursson, Thuc Anh Ngo, Niels Thue Olsen, Yanping Chang, Olaf Walter Franzen, Thomas Engstrøm, Peter Clemmensen, Peter Skov Olsen, Hans Gustav Hørsted Thyregod

166 Citationer (Scopus)

Abstract

BACKGROUND: The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize all-comers with severe native aortic valve stenosis to either transcatheter aortic valve replacement (TAVR) with the CoreValve self-expanding bioprosthesis or surgical aortic valve replacement (SAVR), including a lower-risk patient population than previous trials. This article reports 2-year clinical and echocardiographic outcomes from the NOTION trial.

METHODS AND RESULTS: Two-hundred eighty patients from 3 centers in Denmark and Sweden were randomized to either TAVR (n=145) or SAVR (n=135) with follow-up planned for 5 years. There was no difference in all-cause mortality at 2 years between TAVR and SAVR (8.0% versus 9.8%, respectively; P=0.54) or cardiovascular mortality (6.5% versus 9.1%; P=0.40). The composite outcome of all-cause mortality, stroke, or myocardial infarction was also similar (15.8% versus 18.8%, P=0.43). Forward-flow hemodynamics were improved following both procedures, with effective orifice area significantly more improved after TAVR than SAVR (effective orifice area, 1.7 versus 1.4 cm(2) at 3 months). Mean valve gradients were similar after TAVR and SAVR. When patients were categorized according to Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) (<4% versus ≥4%), there was no statistically significant difference for TAVR and SAVR groups in the composite outcome for low-risk (14.7%, 95% confidence interval, 8.3-21.2 versus 16.8%; 95% confidence interval, 9.7-23.8; P=0.58) or intermediate-risk patients (21.1% versus 27.1%; P=0.59).

CONCLUSIONS: Two-year results from the NOTION trial demonstrate the continuing safety and effectiveness of TAVR in lower-risk patients. Longer-term data are needed to verify the durability of this procedure in this patient population.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01057173.

Originalsprog	Engelsk
Tidsskrift	Circulation. Cardiovascular interventions
Vol/bind	9
Udgave nummer	6
Sider (fra-til)	pii: e003665
ISSN	1941-7640
DOI	https://doi.org/10.1161/CIRCINTERVENTIONS.115.003665
Status	Udgivet - jun. 2016

Adgang til dokumentet

10.1161/CIRCINTERVENTIONS.115.003665

Fingeraftryk

Dyk ned i forskningsemnerne om 'Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Søndergaard, L., Steinbrüchel, D. A., Ihlemann, N., Nissen, H., Kjeldsen, B. J., Petursson, P., Ngo, T. A., Olsen, N. T., Chang, Y., Franzen, O. W., Engstrøm, T., Clemmensen, P., Olsen, P. S., & Thyregod, H. G. H. (2016). Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. Circulation. Cardiovascular interventions, 9(6), pii: e003665. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003665

Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. / Søndergaard, Lars ; Steinbrüchel, Daniel Andreas ; Ihlemann, Nikolaj et al.
I: Circulation. Cardiovascular interventions, Bind 9, Nr. 6, 06.2016, s. pii: e003665.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Søndergaard, L , Steinbrüchel, DA , Ihlemann, N, Nissen, H, Kjeldsen, BJ, Petursson, P, Ngo, TA, Olsen, NT, Chang, Y, Franzen, OW, Engstrøm, T, Clemmensen, P, Olsen, PS & Thyregod, HGH 2016, 'Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial', Circulation. Cardiovascular interventions, bind 9, nr. 6, s. pii: e003665. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003665

Søndergaard L , Steinbrüchel DA , Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P et al. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. Circulation. Cardiovascular interventions. 2016 jun.;9(6):pii: e003665. doi: 10.1161/CIRCINTERVENTIONS.115.003665

Søndergaard, Lars ; Steinbrüchel, Daniel Andreas ; Ihlemann, Nikolaj et al. / Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement : The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. I: Circulation. Cardiovascular interventions. 2016 ; Bind 9, Nr. 6. s. pii: e003665.

@article{a16d53d2d0b04fa789bba8569b8ceda0,

title = "Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial",

abstract = "BACKGROUND: The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize all-comers with severe native aortic valve stenosis to either transcatheter aortic valve replacement (TAVR) with the CoreValve self-expanding bioprosthesis or surgical aortic valve replacement (SAVR), including a lower-risk patient population than previous trials. This article reports 2-year clinical and echocardiographic outcomes from the NOTION trial.METHODS AND RESULTS: Two-hundred eighty patients from 3 centers in Denmark and Sweden were randomized to either TAVR (n=145) or SAVR (n=135) with follow-up planned for 5 years. There was no difference in all-cause mortality at 2 years between TAVR and SAVR (8.0% versus 9.8%, respectively; P=0.54) or cardiovascular mortality (6.5% versus 9.1%; P=0.40). The composite outcome of all-cause mortality, stroke, or myocardial infarction was also similar (15.8% versus 18.8%, P=0.43). Forward-flow hemodynamics were improved following both procedures, with effective orifice area significantly more improved after TAVR than SAVR (effective orifice area, 1.7 versus 1.4 cm(2) at 3 months). Mean valve gradients were similar after TAVR and SAVR. When patients were categorized according to Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) (<4% versus ≥4%), there was no statistically significant difference for TAVR and SAVR groups in the composite outcome for low-risk (14.7%, 95% confidence interval, 8.3-21.2 versus 16.8%; 95% confidence interval, 9.7-23.8; P=0.58) or intermediate-risk patients (21.1% versus 27.1%; P=0.59).CONCLUSIONS: Two-year results from the NOTION trial demonstrate the continuing safety and effectiveness of TAVR in lower-risk patients. Longer-term data are needed to verify the durability of this procedure in this patient population.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01057173.",

keywords = "Journal Article",

author = "Lars S{\o}ndergaard and Steinbr{\"u}chel, {Daniel Andreas} and Nikolaj Ihlemann and Henrik Nissen and Kjeldsen, {Bo Juel} and Petur Petursson and Ngo, {Thuc Anh} and Olsen, {Niels Thue} and Yanping Chang and Franzen, {Olaf Walter} and Thomas Engstr{\o}m and Peter Clemmensen and Olsen, {Peter Skov} and Thyregod, {Hans Gustav H{\o}rsted}",

note = "{\textcopyright} 2016 American Heart Association, Inc.",

year = "2016",

month = jun,

doi = "10.1161/CIRCINTERVENTIONS.115.003665",

language = "English",

volume = "9",

pages = "pii: e003665",

journal = "Circulation. Cardiovascular interventions",

issn = "1941-7640",

publisher = "Lippincott Williams & Wilkins",

number = "6",

}

TY - JOUR

T1 - Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement

T2 - The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial

AU - Søndergaard, Lars

AU - Steinbrüchel, Daniel Andreas

AU - Ihlemann, Nikolaj

AU - Nissen, Henrik

AU - Kjeldsen, Bo Juel

AU - Petursson, Petur

AU - Ngo, Thuc Anh

AU - Olsen, Niels Thue

AU - Chang, Yanping

AU - Franzen, Olaf Walter

AU - Engstrøm, Thomas

AU - Clemmensen, Peter

AU - Olsen, Peter Skov

AU - Thyregod, Hans Gustav Hørsted

PY - 2016/6

Y1 - 2016/6

N2 - BACKGROUND: The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize all-comers with severe native aortic valve stenosis to either transcatheter aortic valve replacement (TAVR) with the CoreValve self-expanding bioprosthesis or surgical aortic valve replacement (SAVR), including a lower-risk patient population than previous trials. This article reports 2-year clinical and echocardiographic outcomes from the NOTION trial.METHODS AND RESULTS: Two-hundred eighty patients from 3 centers in Denmark and Sweden were randomized to either TAVR (n=145) or SAVR (n=135) with follow-up planned for 5 years. There was no difference in all-cause mortality at 2 years between TAVR and SAVR (8.0% versus 9.8%, respectively; P=0.54) or cardiovascular mortality (6.5% versus 9.1%; P=0.40). The composite outcome of all-cause mortality, stroke, or myocardial infarction was also similar (15.8% versus 18.8%, P=0.43). Forward-flow hemodynamics were improved following both procedures, with effective orifice area significantly more improved after TAVR than SAVR (effective orifice area, 1.7 versus 1.4 cm(2) at 3 months). Mean valve gradients were similar after TAVR and SAVR. When patients were categorized according to Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) (<4% versus ≥4%), there was no statistically significant difference for TAVR and SAVR groups in the composite outcome for low-risk (14.7%, 95% confidence interval, 8.3-21.2 versus 16.8%; 95% confidence interval, 9.7-23.8; P=0.58) or intermediate-risk patients (21.1% versus 27.1%; P=0.59).CONCLUSIONS: Two-year results from the NOTION trial demonstrate the continuing safety and effectiveness of TAVR in lower-risk patients. Longer-term data are needed to verify the durability of this procedure in this patient population.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01057173.

AB - BACKGROUND: The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize all-comers with severe native aortic valve stenosis to either transcatheter aortic valve replacement (TAVR) with the CoreValve self-expanding bioprosthesis or surgical aortic valve replacement (SAVR), including a lower-risk patient population than previous trials. This article reports 2-year clinical and echocardiographic outcomes from the NOTION trial.METHODS AND RESULTS: Two-hundred eighty patients from 3 centers in Denmark and Sweden were randomized to either TAVR (n=145) or SAVR (n=135) with follow-up planned for 5 years. There was no difference in all-cause mortality at 2 years between TAVR and SAVR (8.0% versus 9.8%, respectively; P=0.54) or cardiovascular mortality (6.5% versus 9.1%; P=0.40). The composite outcome of all-cause mortality, stroke, or myocardial infarction was also similar (15.8% versus 18.8%, P=0.43). Forward-flow hemodynamics were improved following both procedures, with effective orifice area significantly more improved after TAVR than SAVR (effective orifice area, 1.7 versus 1.4 cm(2) at 3 months). Mean valve gradients were similar after TAVR and SAVR. When patients were categorized according to Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) (<4% versus ≥4%), there was no statistically significant difference for TAVR and SAVR groups in the composite outcome for low-risk (14.7%, 95% confidence interval, 8.3-21.2 versus 16.8%; 95% confidence interval, 9.7-23.8; P=0.58) or intermediate-risk patients (21.1% versus 27.1%; P=0.59).CONCLUSIONS: Two-year results from the NOTION trial demonstrate the continuing safety and effectiveness of TAVR in lower-risk patients. Longer-term data are needed to verify the durability of this procedure in this patient population.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01057173.

KW - Journal Article

U2 - 10.1161/CIRCINTERVENTIONS.115.003665

DO - 10.1161/CIRCINTERVENTIONS.115.003665

M3 - Journal article

C2 - 27296202

SN - 1941-7640

VL - 9

SP - pii: e003665

JO - Circulation. Cardiovascular interventions

JF - Circulation. Cardiovascular interventions

IS - 6

ER -